Palbociclib Therapy - 28 day. NCCP National SACT Regimen. HSE.

Regulatory approval published by the Health Service Executive.

Citation

Palbociclib Therapy - 28 day, 2025, version number 5, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6457/414_v5_Palbociclib_o9nHDn7.pdf

View API

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication Statements
Treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor 3
Treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with fulvestrant in women who have received prior endocrine therapy 3

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
HSE (1) ER positive, HER2-negative Invasive Breast Carcinoma Fulvestrant, Palbociclib
HSE (1) HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Palbociclib
HSE (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Palbociclib
HSE (1) ER positive, HER2-negative Invasive Breast Carcinoma Letrozole, Palbociclib
HSE (1) HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Palbociclib
HSE (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Palbociclib